Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending January 2015. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibilities (PDMRs), and Connected Persons in accordance with DTR 3.1.4R(1)(a) and (c).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share acquisition details under the GSK ShareReward Plan.
- Transaction Date: January 12, 2015
- Share Price: 1,413.96 pence per Ordinary Share
- Plan Type: ShareReward Plan (Personal contribution and GSK matching elements)
Material Changes
No material changes to financial performance or operations are reported in this filing. The document details routine share acquisitions by specific individuals rather than corporate financial changes.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The content is limited to the disclosure of specific share transactions.
Important Facts for Investors
- Executive Participation: Multiple Directors and PDMRs, including Sir Andrew Witty and Dr P J T Vallance, acquired shares on January 12, 2015.
- Transaction Volume: Most listed individuals acquired 9 shares under the personal contribution element and 9 shares under the matching element. Dr P J T Vallance acquired 8 shares in each element.
- Connected Persons: Mrs K Thomson (connected to Mr P C Thomson) acquired 1 share under each element of the plan.
- Market Price: The transactions occurred at a price of 1,413.96 pence per share.